Ebola hemorrhagic fever (EHF) and Marburg hemorrhagic fever (MHF) are rare viral diseases, endemic to central Africa. The overall burden of EHF and MHF is small in comparison to the more common protozoan, helminth, and bacterial diseases typically referred to as neglected tropical diseases (NTDs). However, EHF and MHF outbreaks typically occur in resource-limited settings, and many aspects of these outbreaks are a direct consequence of impoverished conditions. We will discuss aspects of EHF and MHF disease, in comparison to the “classic” NTDs, and examine potential ways forward in the prevention and control of EHF and MHF in sub-Saharan Africa, as well as examine the potential for application of novel vaccines or antiviral drugs for prevention or control of EHF and MHF among populations at highest risk for disease.
References
[1]
Sanchez A, Geisbert TW, Feldmann H (2007) Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields Virology: Lippincott Williams&Wilkins.
[2]
Semmler IA (1998) Ebola goes pop: the filovirus from literature into film. Lit Med 17: 149–174. doi: 10.1353/lm.1998.0006
[3]
Leroy EM, Gonzalez JP, Baize S (2011) Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect 17: 964–976. doi: 10.1111/j.1469-0691.2011.03535.x
Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, et al. (2002) Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287: 2391–2405. doi: 10.1001/jama.287.18.2391
[6]
Dias MB, Reyes-Gonzalez L, Veloso FM, Casman EA (2010) Effects of the USA PATRIOT Act and the 2002 Bioterrorism Preparedness Act on select agent research in the United States. Proc Natl Acad Sci U S A 107: 9556–9561. doi: 10.1073/pnas.0915002107
[7]
Burki TK (2011) USA focuses on Ebola vaccine but research gaps remain. Lancet 378: 389. doi: 10.1016/S0140-6736(11)61194-X
[8]
Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, et al. (2009) Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 9: 723–728. doi: 10.1089/vbz.2008.0167
[9]
MacNeil A, Farnon EC, Wamala J, Okware S, Cannon DL, et al. (2010) Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis 16: 1969–1972. doi: 10.3201/eid1612.100627
[10]
Wamala JF, Lukwago L, Malimbo M, Nguku P, Yoti Z, et al. (2010) Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007–2008. Emerg Infect Dis 16: 1087–1092. doi: 10.3201/eid1607.091525
[11]
Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, et al. (2005) Fruit bats as reservoirs of Ebola virus. Nature 438: 575–576. doi: 10.1038/438575a
[12]
Pourrut X, Delicat A, Rollin PE, Ksiazek TG, Gonzalez JP, et al. (2007) Spatial and temporal patterns of Zaire ebolavirus antibody prevalence in the possible reservoir bat species. J Infect Dis 196: Suppl 2S176–S183. doi: 10.1086/520541
[13]
Towner JS, Pourrut X, Albarino CG, Nkogue CN, Bird BH, et al. (2007) Marburg virus infection detected in a common African bat. PLoS ONE 2: e764. doi:10.1371/journal.pone.0000764.
[14]
Towner JS, Amman BR, Sealy TK, Carroll SA, Comer JA, et al. (2009) Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 5: e1000536. doi:10.1371/journal.ppat.1000536.
[15]
Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, et al. (2009) Discovery of swine as a host for the Reston ebolavirus. Science 325: 204–206. doi: 10.1126/science.1172705
[16]
Taniguchi S, Watanabe S, Masangkay JS, Omatsu T, Ikegami T, et al. (2011) Reston ebolavirus antibodies in bats, the Philippines. Emerg Infect Dis 17: 1559–1560. doi: 10.3201/eid1708.101693
[17]
Baron RC, McCormick JB, Zubeir OA (1983) Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ 61: 997–1003.
[18]
Roels TH, Bloom AS, Buffington J, Muhungu GL, Mac Kenzie WR, et al. (1999) Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: risk factors for patients without a reported exposure. J Infect Dis 179: Suppl 1S92–S97. doi: 10.1086/514286
[19]
Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, et al. (1999) Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179: Suppl 1S87–91. doi: 10.1086/514284
[20]
Francesconi P, Yoti Z, Declich S, Onek PA, Fabiani M, et al. (2003) Ebola hemorrhagic fever transmission and risk factors of contacts, Uganda. Emerg Infect Dis 9: 1430–1437. doi: 10.3201/eid0911.030339
[21]
Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, et al. (2007) Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 196: Suppl 2S142–S147. doi: 10.1086/520545
[22]
Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, et al. (1999) Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179: Suppl 1S177–S187. doi: 10.1086/514321
[23]
Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, et al. (2004) Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 78: 4330–4341. doi: 10.1128/JVI.78.8.4330-4341.2004
[24]
Anonymous (1978) Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 56: 271–293.
[25]
Anonymous (1978) Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 56: 247–270.
[26]
Khan AS, Tshioko FK, Heymann DL, Le Guenno B, Nabeth P, et al. (1999) The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179: Suppl 1S76–S86. doi: 10.1086/514306
[27]
Tomori O, Bertolli J, Rollin PE, Fleerackers Y, Guimard Y, et al. (1999) Serologic survey among hospital and health center workers during the Ebola hemorrhagic fever outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179: Suppl 1S98–S101. doi: 10.1086/514307
[28]
CDC (2001) Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001. MMWR Morb Mortal Wkly Rep 50: 73–77.
[29]
Kerstiens B, Matthys F (1999) Interventions to control virus transmission during an outbreak of Ebola hemorrhagic fever: experience from Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179: Suppl 1S263–267. doi: 10.1086/514320
[30]
Guimard Y, Bwaka MA, Colebunders R, Calain P, Massamba M, et al. (1999) Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179: Suppl 1S268–S273. doi: 10.1086/514315
[31]
Ndambi R, Akamituna P, Bonnet MJ, Tukadila AM, Muyembe-Tamfum JJ, et al. (1999) Epidemiologic and clinical aspects of the Ebola virus epidemic in Mosango, Democratic Republic of the Congo, 1995. J Infect Dis 179: Suppl 1S8–S10. doi: 10.1086/514297
[32]
Lamunu M, Lutwama JJ, Kamugisha J, Opio A, Nambooze J, et al. (2004) Containing a haemorrhagic fever epidemic: the Ebola experience in Uganda (October 2000-January 2001). Int J Infect Dis 8: 27–37. doi: 10.1016/j.ijid.2003.04.001
[33]
Jeffs B, Roddy P, Weatherill D, de la Rosa O, Dorion C, et al. (2007) The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. I. Lessons learned in the hospital. J Infect Dis 196: Suppl 2S154–S161. doi: 10.1086/520548
[34]
Roddy P, Weatherill D, Jeffs B, Abaakouk Z, Dorion C, et al. (2007) The Medecins Sans Frontieres intervention in the Marburg hemorrhagic fever epidemic, Uige, Angola, 2005. II. lessons learned in the community. J Infect Dis 196: Suppl 2S162–S167. doi: 10.1086/520544
[35]
MacNeil A, Farnon EC, Morgan OW, Gould P, Boehmer TK, et al. (2011) Filovirus outbreak detection and surveillance: lessons from Bundibugyo. J Infect Dis 204: Suppl 3S761–S767. doi: 10.1093/infdis/jir294
[36]
Bwaka MA, Bonnet MJ, Calain P, Colebunders R, De Roo A, et al. (1999) Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. J Infect Dis 179: Suppl 1S1–S7. doi: 10.1086/514308
[37]
Colebunders R, Tshomba A, Van Kerkhove MD, Bausch DG, Campbell P, et al. (2007) Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment. J Infect Dis 196: Suppl 2S148–S153. doi: 10.1086/520543
[38]
Smith DH, Johnson BK, Isaacson M, Swanapoel R, Johnson KM, et al. (1982) Marburg-virus disease in Kenya. Lancet 1: 816–820. doi: 10.1016/S0140-6736(82)91871-2
[39]
Bausch DG, Nichol ST, Muyembe-Tamfum JJ, Borchert M, Rollin PE, et al. (2006) Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med 355: 909–919. doi: 10.1056/NEJMoa051465
[40]
Pourrut X, Souris M, Towner JS, Rollin PE, Nichol ST, et al. (2009) Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus. BMC Infect Dis 9: 159. doi: 10.1186/1471-2334-9-159
[41]
Timen A, Koopmans MP, Vossen AC, van Doornum GJ, Gunther S, et al. (2009) Response to imported case of Marburg hemorrhagic fever, the Netherland. Emerg Infect Dis 15: 1171–1175. doi: 10.3201/eid1508.090015
[42]
Georges AJ, Leroy EM, Renaut AA, Benissan CT, Nabias RJ, et al. (1999) Ebola hemorrhagic fever outbreaks in Gabon, 1994–1997: epidemiologic and health control issues. J Infect Dis 179: Suppl 1S65–S75. doi: 10.1086/514290
[43]
Leroy EM, Rouquet P, Formenty P, Souquiere S, Kilbourne A, et al. (2004) Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 303: 387–390. doi: 10.1126/science.1092528
[44]
Nkoghe D, Kone ML, Yada A, Leroy E (2011) A limited outbreak of Ebola haemorrhagic fever in Etoumbi, Republic of Congo, 2005. Trans R Soc Trop Med Hyg 105: 466–472. doi: 10.1016/j.trstmh.2011.04.011
[45]
Adjemian J, Farnon EC, Tschioko F, Wamala JF, Byaruhanga E, et al. (2011) Outbreak of Marburg hemorrhagic fever among miners in Kamwenge and Ibanda Districts, Uganda, 2007. J Infect Dis 204: Suppl 3S796–S799. doi: 10.1093/infdis/jir312
[46]
Swanepoel R, Smit SB, Rollin PE, Formenty P, Leman PA, et al. (2007) Studies of reservoir hosts for Marburg virus. Emerg Infect Dis 13: 1847–1851. doi: 10.3201/eid1312.071115
[47]
Miranda ME, Miranda NL (2011) Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis 204: Suppl 3S757–760. doi: 10.1093/infdis/jir296
[48]
Miranda ME, Ksiazek TG, Retuya TJ, Khan AS, Sanchez A, et al. (1999) Epidemiology of Ebola (subtype Reston) virus in the Philippines, 1996. J Infect Dis 179: Suppl 1S115–S119. doi: 10.1086/514314
[49]
Kobinger GP, Leung A, Neufeld J, Richardson JS, Falzarano D, et al. (2011) Replication, pathogenicity, shedding, and transmission of Zaire ebolavirus in pigs. J Infect Dis 204: 200–208. doi: 10.1093/infdis/jir077
[50]
Marsh GA, Haining J, Robinson R, Foord A, Yamada M, et al. (2011) Ebola Reston virus infection of pigs: clinical significance and transmission potential. J Infect Dis 204: Suppl 3S804–S809. doi: 10.1093/infdis/jir300
[51]
Liese B, Rosenberg M, Schratz A (2010) Programmes, partnerships, and governance for elimination and control of neglected tropical diseases. Lancet 375: 67–76. doi: 10.1016/S0140-6736(09)61749-9
Molyneux DH, Hotez PJ, Fenwick A (2005) “Rapid-impact interventions”: how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2: e336. doi:10.1371/journal.pmed.0020336.
[54]
Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007) Control of neglected tropical diseases. N Engl J Med 357: 1018–1027. doi: 10.1056/NEJMra064142
[55]
(2011) Working to overcome the global impact of neglected tropical diseases - summary. Wkly Epidemiol Rec 86: 113–120.
[56]
Hotez PJ, Fenwick A, Savioli L, Molyneux DH (2009) Rescuing the bottom billion through control of neglected tropical diseases. Lancet 373: 1570–1575. doi: 10.1016/S0140-6736(09)60233-6
[57]
TDR/WHO (2007) Ten year vision strategy. Fostering an effective global research effort on infectious diseases of poverty in which disease endemic countries play a pivotal role. Geneva: TDR/World Health Organization.
[58]
Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, et al. (2006) Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 3: e102. doi:10.1371/journal.pmed.0030102.
[59]
Mathers CD, Ezzati M, Lopez AD (2007) Measuring the burden of neglected tropical diseases: the global burden of disease framework. PLoS Negl Trop Dis 1: e114. doi:10.1371/journal.pntd.0000114.
[60]
Kuhn JH, Calisher CH (2008) Filoviruses: a compendium of 40 years of epidemiological, clinical, and laboratory studies. New York: Springer.
[61]
Busico KM, Marshall KL, Ksiazek TG, Roels TH, Fleerackers Y, et al. (1999) Prevalence of IgG antibodies to Ebola virus in individuals during an Ebola outbreak, Democratic Republic of the Congo, 1995. J Infect Dis 179: Suppl 1S102–S107. doi: 10.1086/514309
[62]
Gonzalez JP, Nakoune E, Slenczka W, Vidal P, Morvan JM (2000) Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic. Microbes Infect 2: 39–44. doi: 10.1016/S1286-4579(00)00287-2
[63]
Becquart P, Wauquier N, Mahlakoiv T, Nkoghe D, Padilla C, et al. (2010) High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS ONE 5: e9126. doi:10.1371/journal.pone.0009126.
[64]
MacNeil A, Farnon EC, Morgan OW, Gould P, Boehmer TK, et al. (2011) Filovirus outbreak detection and surveillance: lessons from Bundibugyo. J Infect Dis 204: Suppl 3S761–S767. doi: 10.1093/infdis/jir294
[65]
Jezek Z, Szczeniowski MY, Muyembe-Tamfum JJ, McCormick JB, Heymann DL (1999) Ebola between outbreaks: intensified Ebola hemorrhagic fever surveillance in the Democratic Republic of the Congo, 1981–1985. J Infect Dis 179: Suppl 1S60–S64. doi: 10.1086/514295
[66]
Accorsi S, Fabiani M, Lukwiya M, Ravera M, Costanzi A, et al. (2001) Impact of insecurity, the AIDS epidemic, and poverty on population health: disease patterns and trends in Northern Uganda. Am J Trop Med Hyg 64: 214–221.
[67]
Hewlett BS, Epelboin A, Hewlett BL, Formenty P (2005) Medical anthropology and Ebola in Congo: cultural models and humanistic care. Bull Soc Pathol Exot 98: 230–236.
[68]
Hewlett BL, Hewlett BS (2005) Providing care and facing death: nursing during Ebola outbreaks in central Africa. J Transcult Nurs 16: 289–297. doi: 10.1177/1043659605278935
[69]
De Roo A, Ado B, Rose B, Guimard Y, Fonck K, et al. (1998) Survey among survivors of the 1995 Ebola epidemic in Kikwit, Democratic Republic of Congo: their feelings and experiences. Trop Med Int Health 3: 883–885. doi: 10.1046/j.1365-3156.1998.00322.x
[70]
Kalongi Y, Mwanza K, Tshisuaka M, Lusiama N, Ntando E, et al. (1999) Isolated case of Ebola hemorrhagic fever with mucormycosis complications, Kinshasa, Democratic Republic of the Congo. J Infect Dis 179: Suppl 1S15–S17. doi: 10.1086/514301
[71]
Kibadi K, Mupapa K, Kuvula K, Massamba M, Ndaberey D, et al. (1999) Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis 179: Suppl 1S13–S14. doi: 10.1086/514288
[72]
Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, et al. (1999) Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 179: Suppl 1S28–S35. doi: 10.1086/514318
[73]
Wendo C (2001) Caring for the survivors of Uganda's Ebola epidemic one year on. Lancet 358: 1350. doi: 10.1016/S0140-6736(01)06467-4
[74]
Borchert M, Mulangu S, Swanepoel R, Libande ML, Tshomba A, et al. (2006) Serosurvey on household contacts of Marburg hemorrhagic fever patients. Emerg Infect Dis 12: 433–439. doi: 10.3201/eid1205.050622
[75]
Bausch DG (2001) The Ebola Virus …… and the Challenges to Health Research in Africa. United Nations Chronicle 38: 6–13.
[76]
Accorsi S, Fabiani M, Nattabi B, Corrado B, Iriso R, et al. (2005) The disease profile of poverty: morbidity and mortality in northern Uganda in the context of war, population displacement and HIV/AIDS. Trans R Soc Trop Med Hyg 99: 226–233. doi: 10.1016/j.trstmh.2004.09.008
[77]
Bethony JM, Cole RN, Guo X, Kamhawi S, Lightowlers MW, et al. (2011) Vaccines to combat the neglected tropical diseases. Immunol Rev 239: 237–270. doi: 10.1111/j.1600-065X.2010.00976.x
[78]
Moran M, Guzman J, Ropars AL, McDonald A, Jameson N, et al. (2009) Neglected disease research and development: how much are we really spending? PLoS Med 6: e30. doi:10.1371/journal.pmed.1000030.
[79]
Centers for Disease Control and Prevention (CDC) (2011) Progress toward global eradication of dracunculiasis, January 2010-June 2011. MMWR Morb Mortal Wkly Rep 60: 1450–1453.
Baker MC, Mathieu E, Fleming FM, Deming M, King JD, et al. (2010) Mapping, monitoring, and surveillance of neglected tropical diseases: towards a policy framework. Lancet 375: 231–238. doi: 10.1016/S0140-6736(09)61458-6
[82]
Marchal B, Van Dormael M, Pirard M, Cavalli A, Kegels G, et al. (2011) Neglected tropical disease (NTD) control in health systems: the interface between programmes and general health services. Acta Trop 120: Suppl 1S177–S185. doi: 10.1016/j.actatropica.2011.02.017
[83]
WHO/CDC (2010) Technical guidelines for integrated disease surveillance and response in the African region. Brazzaville, Republic of Congo, and Atlanta, USA: WHO and CDC.
[84]
Nsubuga P, Brown WG, Groseclose SL, Ahadzie L, Talisuna AO, et al. (2010) Implementing Integrated Disease Surveillance and Response: Four African countries' experience, 1998–2005. Glob Public Health 5: 364–380. doi: 10.1080/17441690903334943
[85]
Feldmann H (2010) Are we any closer to combating Ebola infections? Lancet 375: 1850–1852. doi: 10.1016/S0140-6736(10)60597-1
[86]
Geisbert TW, Bausch DG, Feldmann H (2010) Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 20: 344–357. doi: 10.1002/rmv.661
[87]
Falzarano D, Geisbert TW, Feldmann H (2011) Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines 10: 63–77. doi: 10.1586/erv.10.152
[88]
WHO Global Health Observatory Data RepositoryWorld Health Organization. Available: http://apps.who.int/ghodata/. Accessed 30 May 2012.
